HC Wainwright reiterated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY – Free Report) in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a $2.50 price target on the stock.
Other equities research analysts have also issued reports about the stock. Benchmark reaffirmed a speculative buy rating and issued a $3.00 price objective on shares of Unicycive Therapeutics in a research note on Friday, May 31st. Brookline Capital Management upgraded Unicycive Therapeutics to a strong-buy rating in a report on Tuesday, July 9th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of Buy and a consensus price target of $5.13.
Get Our Latest Stock Report on UNCY
Unicycive Therapeutics Price Performance
Institutional Investors Weigh In On Unicycive Therapeutics
Large investors have recently bought and sold shares of the stock. Rosalind Advisors Inc. acquired a new position in shares of Unicycive Therapeutics during the first quarter valued at about $2,594,000. BVF Inc. IL increased its position in Unicycive Therapeutics by 70.5% in the 1st quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock valued at $4,984,000 after buying an additional 1,493,462 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Unicycive Therapeutics during the 1st quarter worth approximately $36,000. 40.42% of the stock is currently owned by institutional investors and hedge funds.
Unicycive Therapeutics Company Profile
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
See Also
- Five stocks we like better than Unicycive Therapeutics
- What is Short Interest? How to Use It
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- What is Insider Trading? What You Can Learn from Insider Trading
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- What is a Bond Market Holiday? How to Invest and Trade
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.